#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Amy Aspelund Email
VP, Research & Development . Vivaldi Biosciences
How to contact Amy Aspelund
Join and see Amy's contact info for free!Current Roles
Employees:
12Revenue:
$1.9MAbout
Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. Vivaldi's DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.Vivaldi Biosciences Address
3185-A Rampart RoadFort Collins, CO
United States